This is a type of tumor in the pituitary gland, which is located at the base of the brain. This tumor makes too much growth hormone. When this happens, it can cause changes in the body, like making bones and facial features grow larger, and can affect other organs.
Every report comes from a Lived member, sent anonymously.
Have you had Pituitary Removal for Growth Hormone-Secreting Pituitary Adenoma?
A growth hormone-secreting pituitary adenoma is a noncancerous tumor of the pituitary gland, the pea-sized gland at the base of the brain, that releases too much growth hormone. It causes more than 9 in 10 cases of acromegaly, a condition in which years of excess hormone gradually enlarge the hands, feet and face and affect the heart, joints, blood pressure, blood sugar and breathing during sleep. When the excess begins in childhood, before the growth plates in the bones close, it causes gigantism instead: unusually rapid growth in height. The changes usually come on so slowly that people, their families and even their doctors miss them for years. A ring that no longer fits, shoes that need to be wider, a heavier jaw or brow, widening gaps between the teeth, thick oily skin, heavy sweating, a deeper voice, joint pain, snoring and numb hands from carpal tunnel syndrome are common clues. A larger tumor can also press on nearby structures, causing headaches, vision problems or shortages of other pituitary hormones that affect periods, erections, energy and thyroid function.
Researchers do not know exactly why these tumors form. They are most often diagnosed in middle-aged adults, but they can begin at any age. Genetics plays a role in some people, particularly those diagnosed as children or young adults. Variants in a gene called AIP can make these tumors run in families, and inherited syndromes such as multiple endocrine neoplasia type 1 (MEN1), McCune-Albright syndrome and Carney complex can cause a growth hormone-secreting tumor along with tumors or hormone problems in other glands. Tumors linked to these inherited causes tend to start earlier and behave more aggressively. Rarely, the same hormone excess comes from a tumor outside the pituitary, for example in the pancreas or lungs, that releases a hormone signaling the pituitary to overproduce growth hormone. That situation is treated by finding and removing the outside tumor, which is why imaging matters when the pituitary looks normal.
Diagnosis starts with a blood test for insulin-like growth factor 1 (IGF-1). Growth hormone signals the liver to make IGF-1, which drives most of the tissue growth. Growth hormone itself rises and falls throughout the day, but IGF-1 stays fairly steady, so it can be drawn at any time without fasting and gives a more reliable picture. The result is compared with the normal range for the person's age. A level well above that range (more than about 1.3 times the upper limit) in someone with typical physical signs points strongly to acromegaly. Poorly controlled diabetes, liver or kidney disease, pregnancy, estrogen pills and obesity can push results up or down, so a result that does not match the clinical picture is repeated. When results are borderline, an oral glucose tolerance test helps confirm the diagnosis. The person drinks a sugary liquid, and growth hormone is measured several times over the next two hours. Sugar normally pushes growth hormone down to a very low level; with one of these tumors it stays high or even rises. Once the hormone excess is confirmed, an MRI of the pituitary shows the tumor's size and whether it reaches the nerves to the eyes or grows sideways into the cavernous sinuses, the spaces beside the gland that carry major blood vessels and nerves. Tumors 10 millimeters across or smaller are called microadenomas; larger ones, called macroadenomas, are found in about 70 percent of people with acromegaly. Size and spread strongly influence how likely surgery is to cure the condition. A CT scan is used when MRI is not possible. Testing usually also checks other pituitary hormones, including prolactin, which some of these tumors produce as well.
Treatment aims to bring growth hormone and IGF-1 back to normal, control the tumor's size, relieve symptoms and manage complications. Getting IGF-1 into the normal range matters most, because that is what lowers the long-term risks of the condition. For most people, the first step is surgery to remove the tumor through the nose and the sinus behind it (transsphenoidal surgery), without opening the skull. After a successful operation, growth hormone falls quickly. Results depend heavily on the tumor and the surgeon: in pooled studies, about 78 percent of people with microadenomas and about half of those with macroadenomas were in remission afterward, and tumors that have grown into the cavernous sinuses are much harder to remove completely. Surgeons who specialize in pituitary tumors get better results. Possible complications include bleeding, a leak of the fluid around the brain, meningitis, salt and water imbalance and loss of other pituitary hormones. When surgery is not an option or does not fully normalize hormone levels, which is common with larger tumors, medicines control the excess but do not cure it. The most widely used are somatostatin receptor ligands (also called somatostatin analogs), which mimic a natural hormone that switches off growth hormone release and can shrink the tumor. Octreotide (Sandostatin LAR Depot) is injected into a muscle every 4 weeks, and lanreotide (Somatuline Depot) is injected deep under the skin every 4 to 8 weeks. They bring hormone levels to normal in roughly a fifth to two fifths of people, and their main drawbacks are cramps, gas, diarrhea and gallstones. Oral options now exist: octreotide capsules (Mycapssa) for people already doing well on injections, and paltusotine (Palsonify), a tablet approved in 2025. Pasireotide (Signifor LAR), a monthly injection, controls hormone levels in more people but raises blood sugar in most who take it, which weighs heavily for anyone with diabetes or at risk of it. Pegvisomant (Somavert) works differently: it blocks growth hormone's effect on the body rather than its release. It normalizes IGF-1 in roughly 60 to 70 percent of people in everyday use and tends to improve blood sugar, but it does not shrink the tumor, so it is used alone only when tumor growth is not a concern, or combined with a somatostatin drug. It is a self-injected shot under the skin, usually daily, and requires periodic liver tests. Cabergoline, a pill mainly used for prolactin-producing tumors, can help when IGF-1 is only mildly raised or the tumor also makes prolactin, and it is often added to other medicines. Treatment is adjusted step by step, because staying on a medicine that is not working prolongs exposure to excess hormone. Radiation is usually reserved for tumor tissue that remains after surgery and is not controlled by medicine. Focused techniques such as stereotactic radiosurgery stop tumor growth in most people and control hormone excess in about half to two thirds, but the full effect takes 3 to 5 years, so medicine continues in the meantime. Radiation gradually reduces other pituitary hormones over time (about half of people eventually need hormone replacement) and can affect fertility.
When the condition is successfully treated, symptoms generally improve and life expectancy may return to normal. Soft tissue swelling can ease within days of successful surgery, while facial changes improve more slowly, and changes that built up over years, such as joint damage, may not fully reverse. That is one reason a long delay in diagnosis matters. Many people need more than one treatment, and some stay on medicine for years. Uncontrolled disease keeps raising the risk of diabetes, heart disease and early death, so the aim is a normal IGF-1 level, not only feeling better. After surgery, IGF-1 is typically checked every 3 to 6 months in the first year, with an MRI after at least 3 months, then every 6 to 12 months for the next several years. Monitoring continues for life, because hormone levels can rise again and complications need ongoing care. That ongoing care usually covers blood pressure, blood sugar, heart health, sleep apnea and joints. Colon polyps are more common with this condition, so a colonoscopy is generally recommended around the time of diagnosis. People whose other pituitary hormones are low after surgery or radiation take replacement hormones. Fatigue, joint pain, depression and anxiety are more common than in the general population, and frequent injections can be a burden; these deserve attention even when lab results look good.
See a clinician if you notice gradual changes such as a growing ring or shoe size, coarsening facial features or widening gaps between your teeth, especially alongside joint pain, heavy sweating, snoring, carpal tunnel symptoms, or new diabetes or high blood pressure. Asking whether an IGF-1 blood test makes sense can shorten what is often a years-long delay. If you are being treated, contact your care team promptly about signs that other pituitary hormones may be low, such as unusual tiredness, dizziness, nausea or unexplained weight loss, or about medicine side effects such as rising blood sugar readings. Get emergency care for a sudden, severe headache (some people call it the worst of their life) or new double vision, a drooping eyelid or loss of vision. These can signal bleeding or loss of blood flow inside the tumor, called pituitary apoplexy.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Growth Hormone-Secreting Pituitary Adenoma is like, what's helped you, or ask the community a question.